Clinical trial
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or…
NCT00031837 · Gary Morrow, Other · Terminated
Key facts
| NCT number | NCT00031837 |
|---|---|
| Title | Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer |
| Official title | A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer |
| Lead sponsor | Gary Morrow, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer, Thromboembolism |
| Intervention type | Drug, Procedure |
| Interventions | dalteparin, gemcitabine hydrochloride, quality-of-life assessment |
| Enrollment | 400 |
| Start date | Oct 1, 2002 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 14, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: